David W. Cescon

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

Javier Cortés, David W. Cescon, Hope S. Rugo et al. · The Lancet · 2020 · 1.7K citations · Full text

Chemotherapy Versus Placebo, Breast Oncology, Oncology +7

Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer

Javier Cortés, Hope S. Rugo, David W. Cescon et al. · New England Journal of Medicine · 2022 · 968 citations · Full text

Glutathione and Thioredoxin Antioxidant Pathways Synergize to Drive Cancer Initiation and Progression

Isaac S. Harris, Aislinn E. Treloar, Satoshi Inoue et al. · Cancer Cell · 2015 · 948 citations · Full text

Reductive Stress, Tumor Biology, Chemoprevention Strategy +10

Functional variants of OCTN cation transporter genes are associated with Crohn disease

Vanya Peltekova, Richard F. Wintle, Laurence A. Rubin et al. · Nature Genetics · 2004 · 839 citations · Full text

Inflammation, Autoimmune Disease, Mucosal Immunology +9

Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study

Sylvia Adams, Sherene Loi, Deborah Toppmeyer et al. · Annals of Oncology · 2018 · 608 citations